Selective Stem Cell Niche Ablation for Radiation-Free Engraftment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for hematopoietic stem cell engraftment, such as radiation or chemotherapy, cause undesirable side effects and increase the risk of secondary malignancies by ablating both endogenous and differentiated cells, leading to inefficient engraftment and graft failure.
Innovation Solution
Selective ablation of endogenous stem cells using antibodies that target c-kit signaling, followed by introduction of exogenous stem cells after the ablative agent is cleared from the patient's circulation, creating an empty niche for efficient engraftment without affecting other tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If non-selective ablation methods (radiation or chemotherapy) are used to clear endogenous stem cells, then engraftment efficiency is improved, but side effects increase and risk of secondary malignancies increases
Solution Approach 1:
The patent segments the ablation process by using a cocktail of antibodies that specifically target different stem cell populations (CD34+ cells, CD90+ cells, etc.) rather than using non-selective radiation or chemotherapy. This allows selective elimination of endogenous stem cells while preserving other tissues, thereby improving engraftment efficiency without causing the widespread damage and secondary malignancies associated with non-selective methods
Solution Approach 2:
The patent introduces antibody cocktails as intermediary agents that mediate the selective ablation of endogenous stem cells. These antibodies (such as anti-CD34, anti-CD90, anti-Thy-1) act as specific mediators that bind to and eliminate target stem cells through mechanisms like complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity, avoiding the non-specific damage caused by radiation or chemotherapy
2Reliability
If endogenous stem cells are not ablated, then tissue function is maintained, but engraftment efficiency decreases due to niche occupancy
Solution Approach 1:
The patent applies preliminary action by administering the antibody cocktail before stem cell transplantation to pre-clear the bone marrow niche of endogenous stem cells. This preliminary ablation creates empty niches that can be occupied by the transplanted stem cells, ensuring high engraftment efficiency while allowing tissue function to recover after the antibodies are cleared from circulation
Solution Approach 2:
The patent employs periodic action by administering the antibody cocktail at specific time intervals before transplantation and allowing a clearance period before introducing donor stem cells. This timing strategy ensures that endogenous stem cells are eliminated while the antibodies are still present, then allows tissue function to recover when antibodies are cleared, optimizing both engraftment efficiency and tissue function
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances engraftment efficiency and improves tissue function during the engraftment period by specifically targeting hematopoietic stem cells, reducing the need for non-selective ablation methods and minimizing side effects.
Implementation Method 1
an agent which is an antibody that selectively binds c-kit and interferes with c-kit signaling essential for hematopoietic stem cell growth or maintenance
Data Source
Figure 1
Figure 2A~2F
Figure 3A~3D
AI summary
The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment and tolerance.